189 related articles for article (PubMed ID: 23247798)
1. Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-like Abcb4-/- mouse model.
Mende S; Schulte S; Strack I; Hunt H; Odenthal M; Pryymachuck G; Quasdorff M; Demir M; Nierhoff D; Dienes HP; Goeser T; Steffen HM; Töx U
Dig Dis Sci; 2013 May; 58(5):1271-81. PubMed ID: 23247798
[TBL] [Abstract][Full Text] [Related]
2. β-Adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis.
Strack I; Schulte S; Varnholt H; Schievenbusch S; Töx U; Wendland K; Steffen HM; Drebber U; Dienes HP; Odenthal M
Lab Invest; 2011 Feb; 91(2):252-61. PubMed ID: 20921947
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V
J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692
[TBL] [Abstract][Full Text] [Related]
4. Telmisartan attenuates hepatic fibrosis in bile duct-ligated rats.
Yi ET; Liu RX; Wen Y; Yin CH
Acta Pharmacol Sin; 2012 Dec; 33(12):1518-24. PubMed ID: 23103625
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
6. Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
Cai SY; Yu D; Soroka CJ; Wang J; Boyer JL
J Hepatol; 2021 Mar; 74(3):550-559. PubMed ID: 33039404
[TBL] [Abstract][Full Text] [Related]
7. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Fuchsbichler A; Wagner M; Zollner G; Kaser A; Tilg H; Krause R; Lammert F; Langner C; Zatloukal K; Marschall HU; Denk H; Trauner M
Gastroenterology; 2004 Jul; 127(1):261-74. PubMed ID: 15236191
[TBL] [Abstract][Full Text] [Related]
8. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
Yoshihara D; Kugita M; Sasaki M; Horie S; Nakanishi K; Abe T; Aukema HM; Yamaguchi T; Nagao S
PLoS One; 2013; 8(12):e81480. PubMed ID: 24324698
[TBL] [Abstract][Full Text] [Related]
9. Knockout of the Tachykinin Receptor 1 in the Mdr2
Ceci L; Francis H; Zhou T; Giang T; Yang Z; Meng F; Wu N; Kennedy L; Kyritsi K; Meadows V; Wu C; Liangpunsakul S; Franchitto A; Sybenga A; Ekser B; Mancinelli R; Onori P; Gaudio E; Glaser S; Alpini G
Am J Pathol; 2020 Nov; 190(11):2251-2266. PubMed ID: 32712019
[TBL] [Abstract][Full Text] [Related]
10. Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
Ravichandran G; Neumann K; Berkhout LK; Weidemann S; Langeneckert AE; Schwinge D; Poch T; Huber S; Schiller B; Hess LU; Ziegler AE; Oldhafer KJ; Barikbin R; Schramm C; Altfeld M; Tiegs G
J Hepatol; 2019 Oct; 71(4):773-782. PubMed ID: 31173810
[TBL] [Abstract][Full Text] [Related]
11. Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation.
Baghdasaryan A; Claudel T; Kosters A; Gumhold J; Silbert D; Thüringer A; Leski K; Fickert P; Karpen SJ; Trauner M
Gut; 2010 Apr; 59(4):521-30. PubMed ID: 20332524
[TBL] [Abstract][Full Text] [Related]
12. Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2
Fuchs CD; Dixon ED; Hendrikx T; Mlitz V; Wahlström A; Ståhlman M; Scharnagl H; Stojakovic T; Binder CJ; Marschall HU; Trauner M
Hepatol Commun; 2022 Sep; 6(9):2368-2378. PubMed ID: 35691019
[TBL] [Abstract][Full Text] [Related]
13. Expression Analysis of ATP-Binding Cassette Transporters ABCB11 and ABCB4 in Primary Sclerosing Cholangitis and Variety of Pediatric and Adult Cholestatic and Noncholestatic Liver Diseases.
Thoeni C; Waldherr R; Scheuerer J; Schmitteckert S; Roeth R; Niesler B; Cutz E; Flechtenmacher C; Goeppert B; Schirmacher P; Lasitschka F
Can J Gastroenterol Hepatol; 2019; 2019():1085717. PubMed ID: 31886153
[TBL] [Abstract][Full Text] [Related]
14. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
Tedesco D; Thapa M; Chin CY; Ge Y; Gong M; Li J; Gumber S; Speck P; Elrod EJ; Burd EM; Kitchens WH; Magliocca JF; Adams AB; Weiss DS; Mohamadzadeh M; Grakoui A
Gastroenterology; 2018 Jun; 154(8):2178-2193. PubMed ID: 29454797
[TBL] [Abstract][Full Text] [Related]
15. The effect of the angiotensin II receptor, type 1 receptor antagonists, losartan and telmisartan, on thioacetamide-induced liver fibrosis in rats.
Czechowska G; Celinski K; Korolczuk A; Wojcicka G; Dudka J; Bojarska A; Madro A; Brzozowski T
J Physiol Pharmacol; 2016 Aug; 67(4):575-586. PubMed ID: 27779478
[TBL] [Abstract][Full Text] [Related]
16. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.
Moustafa T; Fickert P; Magnes C; Guelly C; Thueringer A; Frank S; Kratky D; Sattler W; Reicher H; Sinner F; Gumhold J; Silbert D; Fauler G; Höfler G; Lass A; Zechner R; Trauner M
Gastroenterology; 2012 Jan; 142(1):140-151.e12. PubMed ID: 22001865
[TBL] [Abstract][Full Text] [Related]
17. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis.
Fickert P; Stöger U; Fuchsbichler A; Moustafa T; Marschall HU; Weiglein AH; Tsybrovskyy O; Jaeschke H; Zatloukal K; Denk H; Trauner M
Am J Pathol; 2007 Aug; 171(2):525-36. PubMed ID: 17600122
[TBL] [Abstract][Full Text] [Related]
18. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.
Tardelli M; Bruschi FV; Fuchs CD; Claudel T; Auer N; Kunczer V; Baumgartner M; A H O Ronda O; Verkade HJ; Stojakovic T; Scharnagl H; Habib A; Zimmermann R; Lotersztajn S; Trauner M
Hepatology; 2020 May; 71(5):1750-1765. PubMed ID: 31505038
[TBL] [Abstract][Full Text] [Related]
19. Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2
Kennedy L; Hargrove L; Demieville J; Karstens W; Jones H; DeMorrow S; Meng F; Invernizzi P; Bernuzzi F; Alpini G; Smith S; Akers A; Meadows V; Francis H
Hepatology; 2018 Sep; 68(3):1042-1056. PubMed ID: 29601088
[TBL] [Abstract][Full Text] [Related]
20. Administration of Human MSC-Derived Extracellular Vesicles for the Treatment of Primary Sclerosing Cholangitis: Preclinical Data in MDR2 Knockout Mice.
Angioni R; Calì B; Vigneswara V; Crescenzi M; Merino A; Sánchez-Rodríguez R; Liboni C; Hoogduijn MJ; Newsome PN; Muraca M; Russo FP; Viola A
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
